vs
Astrana Health, Inc.（ASTH）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
Astrana Health, Inc.的季度营收约是ICU MEDICAL INC的1.8倍（$950.5M vs $540.7M），Astrana Health, Inc.净利率更高（0.7% vs -2.9%，领先3.6%），Astrana Health, Inc.同比增速更快（42.9% vs -14.1%），ICU MEDICAL INC自由现金流更多（$36.0M vs $-6.0M），过去两年Astrana Health, Inc.的营收复合增速更高（53.3% vs -2.3%）
Astrana Health是一家总部位于美国的价值导向型医疗服务提供商，主要服务全美符合联邦医保资格的老年群体，提供上门初级护理、慢性病管理及护理协调服务，致力于提升患者健康水平、降低不必要的医疗支出。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
ASTH vs ICUI — 直观对比
营收规模更大
ASTH
是对方的1.8倍
$540.7M
营收增速更快
ASTH
高出57.0%
-14.1%
净利率更高
ASTH
高出3.6%
-2.9%
自由现金流更多
ICUI
多$41.9M
$-6.0M
两年增速更快
ASTH
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $950.5M | $540.7M |
| 净利润 | $6.6M | $-15.7M |
| 毛利率 | — | 37.5% |
| 营业利润率 | 1.9% | 1.0% |
| 净利率 | 0.7% | -2.9% |
| 营收同比 | 42.9% | -14.1% |
| 净利润同比 | 184.4% | 34.0% |
| 每股收益（稀释后） | $0.12 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASTHICUI
| Q4 25 | $950.5M | $540.7M | ||
| Q3 25 | $956.0M | $537.0M | ||
| Q2 25 | $654.8M | $548.9M | ||
| Q1 25 | $620.4M | $604.7M | ||
| Q4 24 | $665.2M | $629.8M | ||
| Q3 24 | $478.7M | $589.1M | ||
| Q2 24 | $486.3M | $596.5M | ||
| Q1 24 | $404.4M | $566.7M |
净利润ASTHICUI
| Q4 25 | $6.6M | $-15.7M | ||
| Q3 25 | $373.0K | $-3.4M | ||
| Q2 25 | $9.4M | $35.3M | ||
| Q1 25 | $6.7M | $-15.5M | ||
| Q4 24 | $-7.8M | $-23.8M | ||
| Q3 24 | $16.1M | $-33.0M | ||
| Q2 24 | $19.2M | $-21.4M | ||
| Q1 24 | $14.8M | $-39.5M |
毛利率ASTHICUI
| Q4 25 | — | 37.5% | ||
| Q3 25 | — | 37.4% | ||
| Q2 25 | — | 37.9% | ||
| Q1 25 | — | 34.7% | ||
| Q4 24 | — | 36.1% | ||
| Q3 24 | — | 34.8% | ||
| Q2 24 | — | 34.8% | ||
| Q1 24 | — | 32.7% |
营业利润率ASTHICUI
| Q4 25 | 1.9% | 1.0% | ||
| Q3 25 | 2.0% | 2.6% | ||
| Q2 25 | 3.1% | 1.9% | ||
| Q1 25 | 3.3% | 2.1% | ||
| Q4 24 | 0.1% | 6.0% | ||
| Q3 24 | 5.9% | 1.4% | ||
| Q2 24 | 6.2% | 1.3% | ||
| Q1 24 | 7.5% | -1.9% |
净利率ASTHICUI
| Q4 25 | 0.7% | -2.9% | ||
| Q3 25 | 0.0% | -0.6% | ||
| Q2 25 | 1.4% | 6.4% | ||
| Q1 25 | 1.1% | -2.6% | ||
| Q4 24 | -1.2% | -3.8% | ||
| Q3 24 | 3.4% | -5.6% | ||
| Q2 24 | 3.9% | -3.6% | ||
| Q1 24 | 3.7% | -7.0% |
每股收益（稀释后）ASTHICUI
| Q4 25 | $0.12 | $-0.63 | ||
| Q3 25 | $0.01 | $-0.14 | ||
| Q2 25 | $0.19 | $1.43 | ||
| Q1 25 | $0.14 | $-0.63 | ||
| Q4 24 | $-0.14 | $-0.97 | ||
| Q3 24 | $0.33 | $-1.35 | ||
| Q2 24 | $0.40 | $-0.88 | ||
| Q1 24 | $0.31 | $-1.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $429.5M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $779.3M | $2.1B |
| 总资产 | $2.2B | $4.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASTHICUI
| Q4 25 | $429.5M | — | ||
| Q3 25 | $463.4M | — | ||
| Q2 25 | $342.1M | — | ||
| Q1 25 | $260.9M | — | ||
| Q4 24 | $290.8M | $308.6M | ||
| Q3 24 | $350.3M | $312.5M | ||
| Q2 24 | $327.7M | $302.6M | ||
| Q1 24 | $337.3M | $251.4M |
股东权益ASTHICUI
| Q4 25 | $779.3M | $2.1B | ||
| Q3 25 | $775.5M | $2.1B | ||
| Q2 25 | $765.5M | $2.1B | ||
| Q1 25 | $745.4M | $2.0B | ||
| Q4 24 | $712.7M | $2.0B | ||
| Q3 24 | $704.6M | $2.0B | ||
| Q2 24 | $678.9M | $2.0B | ||
| Q1 24 | $653.5M | $2.1B |
总资产ASTHICUI
| Q4 25 | $2.2B | $4.1B | ||
| Q3 25 | $2.2B | $4.1B | ||
| Q2 25 | $1.4B | $4.1B | ||
| Q1 25 | $1.3B | $4.2B | ||
| Q4 24 | $1.4B | $4.2B | ||
| Q3 24 | $1.3B | $4.3B | ||
| Q2 24 | $1.3B | $4.3B | ||
| Q1 24 | $1.2B | $4.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.9M | $60.6M |
| 自由现金流经营现金流 - 资本支出 | $-6.0M | $36.0M |
| 自由现金流率自由现金流/营收 | -0.6% | 6.6% |
| 资本支出强度资本支出/营收 | 0.3% | 4.6% |
| 现金转化率经营现金流/净利润 | -0.44× | — |
| 过去12个月自由现金流最近4个季度 | $104.5M | $91.8M |
8季度趋势，按日历期对齐
经营现金流ASTHICUI
| Q4 25 | $-2.9M | $60.6M | ||
| Q3 25 | $10.0M | $56.7M | ||
| Q2 25 | $90.9M | $11.2M | ||
| Q1 25 | $16.6M | $51.3M | ||
| Q4 24 | $-10.9M | $40.2M | ||
| Q3 24 | $34.0M | $36.1M | ||
| Q2 24 | $23.2M | $82.0M | ||
| Q1 24 | $6.0M | $45.8M |
自由现金流ASTHICUI
| Q4 25 | $-6.0M | $36.0M | ||
| Q3 25 | $7.4M | $27.6M | ||
| Q2 25 | $89.5M | $-8.5M | ||
| Q1 25 | $13.6M | $36.7M | ||
| Q4 24 | $-13.5M | $16.1M | ||
| Q3 24 | $31.7M | $16.2M | ||
| Q2 24 | $20.4M | $62.5M | ||
| Q1 24 | $5.6M | $29.9M |
自由现金流率ASTHICUI
| Q4 25 | -0.6% | 6.6% | ||
| Q3 25 | 0.8% | 5.1% | ||
| Q2 25 | 13.7% | -1.5% | ||
| Q1 25 | 2.2% | 6.1% | ||
| Q4 24 | -2.0% | 2.6% | ||
| Q3 24 | 6.6% | 2.7% | ||
| Q2 24 | 4.2% | 10.5% | ||
| Q1 24 | 1.4% | 5.3% |
资本支出强度ASTHICUI
| Q4 25 | 0.3% | 4.6% | ||
| Q3 25 | 0.3% | 5.4% | ||
| Q2 25 | 0.2% | 3.6% | ||
| Q1 25 | 0.5% | 2.4% | ||
| Q4 24 | 0.4% | 3.8% | ||
| Q3 24 | 0.5% | 3.4% | ||
| Q2 24 | 0.6% | 3.3% | ||
| Q1 24 | 0.1% | 2.8% |
现金转化率ASTHICUI
| Q4 25 | -0.44× | — | ||
| Q3 25 | 26.69× | — | ||
| Q2 25 | 9.65× | 0.32× | ||
| Q1 25 | 2.48× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.11× | — | ||
| Q2 24 | 1.21× | — | ||
| Q1 24 | 0.40× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
